



### Editor

Tracy Crooks

Reckitt Benckiser Healthcare International Ltd  
email: [tracy.crooks@reckittbenckiser.com](mailto:tracy.crooks@reckittbenckiser.com)

### Advisory Panel

Elliot Brown

Managing Director, Elliot Brown Consulting Ltd

David Cousins

Head of Safe Medication Practice, National Patient Safety Agency

Alison Ewing

Clinical Director of Pharmacy, Royal Liverpool and Broadgreen University Hospitals NHS Trust

Graeme Ladds

Director, PharSafer Associates Ltd.

Sunayana Shah

Scientific & Medical Affairs Manager at the Proprietary Association of Great Britain (PAGB)

### Publisher

Joe Ridge

### Design & Production

Sarah Beale

### Subscriptions

Jill Monk

email: [subs@euromedcommunications.com](mailto:subs@euromedcommunications.com)

Published by Euromed Communications Ltd  
Passfield Business Centre, Passfield, Liphook,  
Hampshire GU30 7SB, UK  
Tel: +44 (0)1428 752222  
Fax: +44 (0)1428 752223

email: [info@euromedcommunications.com](mailto:info@euromedcommunications.com)  
[www.euromedcommunications.com](http://www.euromedcommunications.com)

Euromed Communications Ltd also publish  
Clinical Research Manual; Paediatric Clinical  
Research Manual, Medical Devices Manual and  
Compendium of Quality of Life Instruments

Copyright: No part of this journal may be reproduced without written permission from the Publishers. The comments of the contributors are their own and are not necessarily endorsed by the Publisher, Editor or Advisory Panel. Accordingly the Publisher, Editor or Advisory Panel accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement. The Editor's decision is final and no correspondence will be entered into. The utmost care has been taken to ensure accuracy of detail, but the publishers cannot accept responsibility for errors or omissions.

© 2012 Euromed Communications Ltd

ISSN 1752-6752

# Contents

February 2012 • Volume 6 Number 1

## 3 Editorial comment

Tracy Crooks

## 4 Successful commercialisation of a REMS program introduction

Whist clinical and commercial responsibilities within a company apply to different teams, risk management and mitigation strategies are central to both  
*Caroline York and Jean Dinwiddie*

## 10 Cost versus quality – the real price you could pay for 'budget' PV

With pharmacovigilance, it is false economy to choose PV services based on cost rather than quality.  
*Steve Proudlove*

## 12 Adverse effects of vaccines – is there a causal relationship?

The US Institutes of Medicine found evidence for a causal relationship between some vaccines and some adverse effects. But concluded that few health problems can be linked to vaccines.

## 14 Product liability insurance for the life sciences industries

The author, an insurance broker and risk adviser, explains how risks, especially product liability risk, are dealt with by insurance companies.  
*Christopher Bryce*

## 18 Evolution of the Japanese Regulatory System

Japan has reorganised its drug regulatory system to form a single unified agency similar to that of Europe and the USA. Clinical data requirements and vigilances are now clearly defined.  
*David Jeffreys*